Table 3.

Distribution of Aβ42/40 ratio and further classification of MCI biomarker-based subgroups

	Aβ42/40 ratio < 0.068	Aβ42/40 ratio ≥ 0.068
LL (n = 59)	10 (17%)—IAP	49 (83%)—LL
IAP (n = 21)	14 (67%)—IAP	7 (33%)—LL
SNAP (n = 55)	36 (66%)—HL	19 (34%)—SNAP
HL (n = 62)	56 (90%)—HL	6 (10%)—SNAP

Data expressed as n (percentage) of patients

Aβ42/40 42-aminoacid isoform of amyloid beta/40-aminoacid isoform of amyloid beta, LL Low-AD likelihood, IAP isolated amyloid pathology, SNAP suspected non-Alzheimer pathology, HL high-AD likelihood, AD Alzheimer’s disease